HomeCompareDTLIF vs JNJ

DTLIF vs JNJ: Dividend Comparison 2026

DTLIF yields 32.84% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTLIF wins by $125.5K in total portfolio value
10 years
DTLIF
DTLIF
● Live price
32.84%
Share price
$6.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$155.7K
Annual income
$22,278.99
Full DTLIF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DTLIF vs JNJ

📍 DTLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTLIFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTLIF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DTLIF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTLIF
Annual income on $10K today (after 15% tax)
$2,791.46/yr
After 10yr DRIP, annual income (after tax)
$18,937.14/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DTLIF beats the other by $14,951.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTLIF + JNJ for your $10,000?

DTLIF: 50%JNJ: 50%
100% JNJ50/50100% DTLIF
Portfolio after 10yr
$93.0K
Annual income
$13,484.20/yr
Blended yield
14.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DTLIF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
0.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTLIF buys
0
JNJ buys
0
No recent congressional trades found for DTLIF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTLIFJNJ
Forward yield32.84%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$155.7K$30.3K
Annual income after 10y$22,278.99$4,689.40
Total dividends collected$109.9K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: DTLIF vs JNJ ($10,000, DRIP)

YearDTLIF PortfolioDTLIF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,984$3,284.07$10,592$272.30+$3.4KDTLIF
2$19,255$4,292.03$11,289$357.73+$8.0KDTLIF
3$26,126$5,523.17$12,123$472.89+$14.0KDTLIF
4$34,959$7,003.81$13,141$629.86+$21.8KDTLIF
5$46,164$8,758.55$14,408$846.81+$31.8KDTLIF
6$60,205$10,809.36$16,021$1,151.60+$44.2KDTLIF
7$77,594$13,174.79$18,122$1,588.22+$59.5KDTLIF
8$98,895$15,869.24$20,930$2,228.20+$78.0KDTLIF
9$124,720$18,902.42$24,792$3,191.91+$99.9KDTLIF
10$155,730$22,278.99$30,274$4,689.40+$125.5KDTLIF

DTLIF vs JNJ: Complete Analysis 2026

DTLIFStock

D2L Corporation provides an online integrated learning platform for learners in higher education, K–12, healthcare, government, and enterprise sectors. It offers Brightspace, a learning platform that combines usability, integrated analytics, and accessibility practices; Brightspace Learning Object Repository to manage learning objects and share content; Brightspace ePortfolio, which combines social sharing and learning concepts for learners; and Brightspace Insights, a solution to predict, measure, and guide student performance. It also provides Brightspace Degree Compass, a Web-based course recommendation tool that guides students' course selection; Brightspace LeaP, an adaptive learning platform to create individualized online learning experience for students; Brightspace Assignment Grader, an online grading tool that improves productivity and work-life balance; Brightspace Binder, a solution for students to collect, organize, and discover learning content; Brightspace Campus Life, an application that provides students with access to their courses, campus news and updates, upcoming events, and more; and Brightspace Course Catalog, a solution that enables users to search for the list of courses. In addition, it offers Brightspace Capture, a solution to record and broadcast media presentations; Brightspace Binder Shop, a solution for users to discover, evaluate, and recommend e-textbooks for learners; Brightspace Open Courses, an open online learning solution; Brightspace Pulse, an application that helps students to stay up to date and prepared by unifying course calendars, assignments, grades, and news; and D2L Wave, a platform for employees to gain new skills by accessing an online catalog of education options from various educational institutions. The company was founded in 1999 and is headquartered in Kitchener, Canada with locations in Toronto, Winnipeg, and Richmond, Canada; Towson, Maryland; Melbourne, Australia; London, United Kingdom; Brazil; and Singapore.

Full DTLIF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DTLIF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTLIF vs SCHDDTLIF vs JEPIDTLIF vs ODTLIF vs KODTLIF vs MAINDTLIF vs ABBVDTLIF vs MRKDTLIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.